|Bid||0.0000 x 1200|
|Ask||0.0000 x 1300|
|Day's Range||0.5510 - 0.7200|
|52 Week Range||0.3701 - 1.2900|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 20, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
(NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today announced second quarter financial results for the second quarter ended June 30, 2020 and summarized recent clinical and corporate developments.
-William Blair Biotech Focus Conference - August 4th\\- 6th-BTIG Virtual Biotechnology Conference - August 10th & 11thRALEIGH, NC / ACCESSWIRE / August 4, 2020 / 9 Meters Biopharma, Inc.
RALEIGH, NC / ACCESSWIRE / July 28, 2020 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today the U.S. Patent and Trademark Office ("USPTO") issued U.S. Pat. No. 10,723,763, titled, Use of Tight Junction Antagonists in the Treatment of Acute Lung Injury and Acute Respiratory Distress, relating to its proprietary investigational agent, larazotide.